Glenmark Pharmaceuticals Ltd share price today (on 22 March 2023).

We Provide Best stock tips for Glenmark Pharmaceuticals Ltd. A1 Intraday Tips is accurate share tips Provider Company in India in Nse market. A1 Intraday Tips, also provide Daily Charts with Nse Share Market current price of Glenmark Pharmaceuticals Ltd with today performance in nse market. Contact Us for Jackpot Stock tips.

Get Free Stock Tips for Glenmark Pharmaceuticals Ltd

BSE: 532296 | NSE: GLENMARK | ISIN: INE935A01035 Market Cap: [Rs.Cr.] 11,673 | Face Value: [Rs.] 1 Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Glenmark Pharmaceuticals Limited, together with its subsidiaries, engages in the manufacture and marketing of pharmaceutical formulations and active pharmaceutical ingredients in India and internationally. The companys products include Crofelemer, a Phase III clinical trial product for HIV-related diarrhoea; GRC 8200, which completed Phase IIb clinical trial for the treatment diabetes; GRC 4039 that completed Phase I clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases
Glenmark Pharmaceuticals Ltd is a research-driven, global, integrated pharmaceutical company. The company is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with five molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. The company engaged in discovery of new molecules both new chemical entities (NCEs) and new biological entities (NBEs). The company operates in five geographical areas: India, United States, Latin America, Europe and Rest of the World. They operate in three segments: specialty, generics and out-licensing. Specialty segment includes manufacture and distribution of branded products of Glenmark. Specialty business is focused on range of therapeutic segments, such as dermatology, internal medicine, respiratory, pediatrics, diabetes, gynecology, oncology. Generics segment consists of finished pharmaceutical products ready for consumption by the patient, marketed under as generic finished dosages with therapeutic equivalence to branded formulations (generics). Out-licensing segment includes the discovery of new chemical entities for subsequent commercialization and out-licensing, as well as contract research services.
Glenmark Pharmaceuticals Ltd was incorporated in the year 1977. In the year 1979, the company entered dermatology market with the launch of 'Candid Cream'. In the year 1980, they started exporting their products. In the year 1983, the company commissioned their first manufacturing facility at Nasik in Maharashtra. In they ear 1984, they established R&D department at Nasik Plant. In the year 1987, they launched Ascoril. In the year 1989, the company started operations in Afghansitan, Srilanka, Kenya and Mauritius. In the year 1982, the company expanded the Nasik plant by acquiring the adjacent plot to include the R&D Department as well as increase in installed production capacity. In the year 1996, the company incorporated a wholly owned subsidiary company namely, Glenmark Exports Pvt Ltd to consolidate their position in international business. In the year 1999, they started marketing their products in Brazil. In the year 2000, they came out with the public issue.
They entered in diabetes segment. Also, they acquired three brands from Lyka Labs. In the year 2001, the company launched API manufacturing business. In the year 2002, they acquired an API manufacturing facility at Ankleshwar, Gujarat from Glaxosmithkline Pharmaceuticals Ltd. In the year 2004, the company entered their first out-licensing deal for discovery R&D with Forest Laboratories for Oglemilast, their CIPD/asthma molecule. They acquired Laboratories Klinger, Brazil together with their ANVISA approved manufacturing facility inorder to expand their operations in the Latin American markets. They commissioned their own manufacturing facility at Goa to service exports to regulated markets, namely USA. In the year 2005, the company launched commercial sales front-end in the US. They commissioned a new manufacturing facility at Baddi, Himachal Pradesh. They entered collaborative agreement on Oglemilast with Teijin Pharma for the Japan region. Also, they announced collaborative agreement with Napa Pharmaceuticals Inc, for their anti-diarrheal compound Crofelemer. The company acquired Servycal S A, a marketing company in Argentina with strengths in oncology.
Also, they acquired Bouwer Bartlett Pty Ltd, a sales and marketing company in South Africa. In the year 2006, the company signed out-licensing deal in discovery R&D with Merck KGaA, Germany for their diabetes molecule, Melogliptin. Their lead molecule Oglemilast (GRC 3886) entered Phase II clinical trials. In the year 2007, the company acquired Medicamenta, a marketing and manufacturing company in the Czech Republic. Their molecule GRC 6211 for the potential treatment of pain, including osteoarthritis pain out-licensed to Eli Lily. They received MHRA, UK approval for their semi-solid manufacturing plant at Baddi. In the year 2008, the company initiated Phase II-b for Oglemilast (GRC 3886) in Asthma. They completed preclinical development for initiating phase I trials for GBR 500, a monoclonal antibody for inflammation. The company's molecule for Rheumatoid Arthritis, GRC 4039, entered Phase I trials. They re-organized their business and incorporated Glenmark Genrics Ltd as a subsidiary company. They received USFDA approval for the state-or-the-art semi-solids manufacturing plant at Baddi. In the year 2009, the company's molecule for neurophatic pain, osteoarthritis, completed the Phase I trials. During the year 2009-10, the company incorporated a subsidiary company, namely Glenmark Generics B.V., Netherlands.
In the year 2010, Crofelemer, a first-in-class anti-diarrhoeal molecule completed phase 3 trials. They received the final approval for Pramipexole Dihydrochloride tablets from the USFDA. Glenmark Generics entered into an exclusive licensing agreement with Par Pharmaceuticals, USA to market Ezetimibe. The company and Sanofi-Aventis signed license agreement to grant Sanofi-Aventis a license for the development and commercialization of novel agents to treat chronic pain. They launched 'Prasugrel', a revolutionary new anti-platelet drug for the management of Acure Coronary Syundrome with PCT (Precutaneous Coronary Intervention) for the first time in India. During the year 2010-11, the company has incorporated a subsidiary company namely, Glenmark Arzneimittel GmbH, Germany. In October 2010, the company won the Frost and Sullivan award for 'Indian Innovator Pharmaceutical Company of the year' in October 2010. The company was chosen as the 'Best Company Across Emerging Markets' 2011, and recognized for the 'Best Overall Pipeline' 2011 by SCRIP, the largest selling and most respected pharmaceutical magazine in the world.
According to the Consolidated - Audited financial statement for the Year of 2012, total net operating revenues increased with 30.43%, from INR 3,089.59 tens of millions to INR 4,029.9 tens of millions. Operating result increased from INR 592.27 tens of millions to INR 714.36 tens of millions which means 20.61% change. The results of the period increased 1.42% reaching INR 464.31 tens of millions at the end of the period against INR 457.83 tens of millions last year. Return on equity (Net income/Total equity) went from 36.19% to 28.56%, the Return On Asset (Net income / Total Asset) went from 8.98% to 7.89% and the Net Profit Margin (Net Income/Net Sales) went from 14.82% to 11.52% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 361.83% compared to 402.94% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 1.13 to 2.72 when compared to the previous year.

Gabriel India Ltd	Gammon India Ltd	Gati Ltd	Genesys International Corporation Ltd
GHCL Ltd	Gujarat Industries Power Co Ltd	GAEL	GANESHHOUC
GDL	GEODESIC	GICHSGFIN	GAIL
GARDENSILK	GEECEE	GEOMETRIC	GILLANDERS
GALLISPAT	GARWALLROP	GEINDSYS	GESHIP
GILLETTE

Our all intraday stock tips,
Under one plan with Unbelievable lowest price
( Equity cash, Nse f&o tips, jackpot tips, sure shot call, btst/stbt call/nifty tips/bank nifty tips)
free trial available for 2 days

 

GITANJALI	GLENMARK	GMBREW	GOACARBON
GODREJPROP	GOLDIAM	GKB	GLOBOFFS
GKWLIMITED	GLOBUSSPR	GMRINFRA	GODREJCP
GMDCLTD	GODFRYPHLP	GOKEX	GOKUL
GLAXO	GLODYNE	GNFC	GODREJIND
GOLDENTOBC	GPIL	GRASIM	GRUH

Daily Intraday free Nifty Level with 90% Accuracy

 

 

GTL	GUJFLUORO	GVKPIL	GPPL
GRAVITA	GSFC	GTOFFSHORE	GUJNRECOKE
GRANULES	GREENPLY	GSKCONS	GUJALKALI
GUJRATGAS	GRAPHITE	GRINDWELL	GSPL
GUJAPOLLO	GULFOILCOR

 

3 to 4 Share Tips & Stock Tips for Nse Intraday traders
to Earn daily Rupees 10000 to 15000
Our all call under in one plan
(equity, fno, jackpot,sure shot, nifty, bank nifty tips )

Nse Listed Companies with Live Charts

(Click on an alphabet below to get a list of nse listed companies
with live charts starting with that Alphabet.)

A	B	C	D	E	F	G	H	I	J
K	L	M	N	O	P	Q	R	S	T
U	V	W	X	Y	Z